Kritische 8-K Meldungen
HOCH Abgang Schlüsselpersonen (06.03.2026)
HOCH Abgang Schlüsselpersonen (02.03.2026)
HOCH Abgang Schlüsselpersonen (25.02.2026)
HOCH Abgang Schlüsselpersonen (13.02.2026)
HOCH Abgang Schlüsselpersonen (10.02.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 06.03.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 02.03.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 25.02.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers |
| 13.02.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ct. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 10.02.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | rical financial statements of the Company. Item 5.02 Departure of Directors or Certain Officers; Election of Directors |
| 14.01.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | rporated by reference into this Item 3.03. Item 5.02 Departure of Directors or Certain Officers; Election of Directors |
| 09.07.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Off |
| 30.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | king to update forward-looking statements. Item 5.02 Departure of Directors or Certain Officers; Election of Directors |
| 15.04.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers |
| 21.03.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 18.10.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 15.05.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | suant to Item 2.02 as Exhibit 99.1 hereto. Item 5.02 Departure of Directors or Certain Officers; Election of Directors |
| 06.01.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Act. ☒ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officer |
Stammdaten
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Unternehmen & Branche
| Name | BiomX Inc. |
|---|---|
| Ticker | PHGE |
| CIK | 0001739174 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,4 Mio. USD |
| Beta | 1,70 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -36,199,000 | 22.19 | 5,783,000 | -1,302,000 | |
| 2025-09-30 | 10-Q | -9,166,000 | 0.29 | 26,168,000 | 10,486,000 | |
| 2025-06-30 | 10-Q | -6,037,000 | 0.19 | 38,050,000 | 19,160,000 | |
| 2025-03-31 | 10-Q | -7,659,000 | 0.33 | 45,654,000 | 24,499,000 | |
| 2024-12-31 | 10-K | -17,727,000 | 58.31 | 43,233,000 | 24,148,000 | |
| 2024-09-30 | 10-Q | 9,642,000 | -0.31 | 59,980,000 | 37,896,000 | |
| 2024-06-30 | 10-Q | 4,471,000 | 0.69 | 68,619,000 | 27,425,000 | |
| 2024-03-31 | 10-Q | -17,327,000 | 2.78 | 81,606,000 | -9,544,000 | |
| 2023-12-31 | 10-K | -26,169,000 | 5.10 | 25,029,000 | 3,081,000 | |
| 2023-09-30 | 10-Q | -7,906,000 | 1.30 | 33,056,000 | 8,154,000 | |
| 2023-06-30 | 10-Q | -6,411,000 | 0.12 | 41,253,000 | 15,865,000 | |
| 2023-03-31 | 10-Q | -6,361,000 | 0.20 | 41,407,000 | 16,146,000 | |
| 2022-12-31 | 10-K | -28,317,000 | 0.95 | 45,531,000 | 21,039,000 | |
| 2022-09-30 | 10-Q | -6,780,000 | 0.23 | 51,901,000 | 26,558,000 | |
| 2022-06-30 | 10-Q | -7,482,000 | 0.25 | 58,382,000 | 32,739,000 | |
| 2022-03-31 | 10-Q | -8,169,000 | 0.27 | 68,744,000 | 40,018,000 | |
| 2021-12-31 | 10-K | -36,226,000 | 1.39 | 77,990,000 | 47,535,000 | |
| 2021-09-30 | 10-Q | -10,031,000 | 0.37 | 81,799,000 | 53,426,000 | |
| 2021-06-30 | 10-Q | -7,336,000 | 0.30 | 61,649,000 | 48,592,000 | |
| 2021-03-31 | 10-Q | -8,402,000 | 67,062,000 | 53,954,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-17 | Yeganeh Reuven | Director, 10% Owner | Open Market Sale | -530,000 | 5.00 | -2,650,000.00 | -128,5% | |
| 2026-03-16 | Yeganeh Reuven | Director, 10% Owner | Open Market Sale | -450,000 | 5.00 | -2,250,000.00 | -109,1% | |
| 2026-03-13 | Yeganeh Reuven | Director, 10% Owner | Open Market Sale | -370,000 | 5.00 | -1,850,000.00 | -89,7% | |
| 2026-03-12 | Yeganeh Reuven | Director, 10% Owner | Open Market Sale | -300,000 | 5.00 | -1,500,000.00 | -72,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.